BR0307595A - Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico - Google Patents

Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico

Info

Publication number
BR0307595A
BR0307595A BR0307595-8A BR0307595A BR0307595A BR 0307595 A BR0307595 A BR 0307595A BR 0307595 A BR0307595 A BR 0307595A BR 0307595 A BR0307595 A BR 0307595A
Authority
BR
Brazil
Prior art keywords
sildenafil
treatment
pde5 inhibitors
polycystic ovarian
ovarian syndrome
Prior art date
Application number
BR0307595-8A
Other languages
English (en)
Inventor
Mahmoud Nizar Ghazzi
Nandan Parmanand Koppiker
Simon Lempriere Westbrook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0307595A publication Critical patent/BR0307595A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE INIBIDORES DE PDE5 TAL COMO SILDENAFIL NO TRATAMENTO DE SìNDROME DE OVáRIO POLICìSTICO". A presente invenção refere-se ao uso de um inibidor de PDE5 de pirazolopirimidinona tal como sildenafil para o tratamento de síndrome do ovário policístico.
BR0307595-8A 2002-02-07 2003-01-27 Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico BR0307595A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35503802P 2002-02-07 2002-02-07
PCT/IB2003/000257 WO2003066061A1 (en) 2002-02-07 2003-01-27 Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome

Publications (1)

Publication Number Publication Date
BR0307595A true BR0307595A (pt) 2005-02-01

Family

ID=27734455

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307595-8A BR0307595A (pt) 2002-02-07 2003-01-27 Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico

Country Status (9)

Country Link
US (1) US20040029891A1 (pt)
EP (1) EP1471917A1 (pt)
JP (1) JP2005519927A (pt)
AU (1) AU2003205926A1 (pt)
BR (1) BR0307595A (pt)
CA (1) CA2475377A1 (pt)
MX (1) MXPA04007713A (pt)
TW (1) TW200303747A (pt)
WO (1) WO2003066061A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2004052390A1 (en) * 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
MXPA05010373A (es) * 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
DK1697371T3 (da) * 2003-12-19 2007-09-17 Bristol Myers Squibb Co Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
EP1853266B1 (en) * 2005-01-10 2011-10-12 Cortendo AB (publ) 2s,4r ketoconazole for treating diabetes, metabolic syndrome and other conditions
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
WO2007114534A1 (en) * 2006-04-04 2007-10-11 Dong-A Pharmaceutical.Co., Ltd. Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
RU2009116632A (ru) * 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
EA201070056A1 (ru) * 2007-06-26 2010-06-30 Солвей Фармасьютикалс Б.В. N-оксид силденафила в качестве пролекарства
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US20130203778A1 (en) * 2010-03-22 2013-08-08 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a pyrimidineone derivative
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
CN106442764B (zh) * 2016-08-31 2019-01-22 王义明 多囊卵巢综合征的诊断和/或分型标志物及制备试剂的用途
EP3927846A4 (en) * 2019-02-20 2023-04-05 Virginia Commonwealth University COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND/OR THERAPY OF DISORDERS CORRELATING WITH DENND1A VARIANT 2
US11376263B2 (en) * 2020-10-08 2022-07-05 Fortress Biotech, Inc. Cyproterone acetate compositions and uses thereof
DE202022104150U1 (de) 2022-07-22 2022-08-11 Malti Arya Eine polypharmazeutische Formulierung als potenzielles Mittel zur Behandlung des polyzystischen Ovarsyndroms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826286T2 (de) * 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
EP1132087A4 (en) * 1998-11-13 2002-06-26 Fujisawa Pharmaceutical Co REMEDIES FOR POLYKYSTIC OVARY SYNDROME
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals

Also Published As

Publication number Publication date
CA2475377A1 (en) 2003-08-14
JP2005519927A (ja) 2005-07-07
US20040029891A1 (en) 2004-02-12
AU2003205926A1 (en) 2003-09-02
EP1471917A1 (en) 2004-11-03
MXPA04007713A (es) 2004-11-10
WO2003066061A1 (en) 2003-08-14
TW200303747A (en) 2003-09-16

Similar Documents

Publication Publication Date Title
BR0307595A (pt) Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico
WO2003074500A3 (en) N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
IL163781A0 (en) Purine derivatives as kinase inhibitors
UY29479A1 (es) Inhibidores de adn-pk
GEP20105081B (en) Pyrrolotriazine compounds as kinase inhibitors
ATE365740T1 (de) Substituierte pyrazolopyrimidine
SV1999000047A (es) Nuevas dihidropirimidinas fef. lea 32792-sv
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
NO20071077L (no) Fosfonatanaloger til HIV-inhibitorforbindelser
BRPI0507312A (pt) derivados de quinolina para uso como inibidores micobacterianos
DE60333746D1 (de) Thienylverbindungen
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
GT200300231A (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
BG108245A (en) Compositions containing imidazotriazinone for nasal application
MX2007001953A (es) Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
WO2007120333A3 (en) Tetracyclic kinase inhibitors
MXPA06000372A (es) Compuestos de silicio y su uso.
EP1605926A4 (en) USE OF PINITOL OR CHIROINOSITOL FOR THE PROTECTION OF THE LIVER
BRPI0417263A (pt) imidazopiridinas para uso como inibidores de secreção gástrica
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
ATE396177T1 (de) Neue kristalline formen eines faktor xa inhibitors
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
MX2007001952A (es) Compuestos y composiciones utiles como inhibidores de catepsina-s.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A., E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.